FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2213280957> ?p ?o ?g. }

• W2213280957 endingPage "61" @default.
• W2213280957 startingPage "157" @default.
• W2213280957 abstract "Iron overload and inflammation might participate in the pathogenesis of insulin resistance in community. The improvement of insulin resistance in hemodialysis (HD) patients is frequently seen after correction of anemia. The aim of this study was to investigate the influence of recobinant humam erythropoietin (Epo) treatment on insulin resistance in non-diabetic HD patients.We investigated the effects of 6 months-duration treatment with Epo on insulin resistance and inflammatory parameters in 16 (6 male/10 female) patients on maintenance HD with renal anemia (hemoglobin concentration </=105 g/l). The control group consisted of 15 patients on HD with renal anemia, without Epo treatment. Further clinical and laboratory variables were observed: fasting blood glucose (FBG), insulin, albumin, iron, total iron binding capacity (TIBC), transferrin saturation (TSAT), ferritin, TNF-alpha, and IL-6. Independent predictors for changes of calculated insulin resistance index by homeostasis model assessment (HOMA-IR) were identified by multivariate linear regression analysis.A significant reduction of insulin levels and therefore significant lowering of HOMA-IR was registered in Epo treated group. It was observed improvement of anemia [Hb 93.90+/-17.34 g/L vs. 116.40+/-21.03 g/L, p: 0.01; Hct 0.28 (0.24-0.31) vs. 0.33% (0.31-0.37), p: 0.01] as well as a trend toward iron stores decrease [ferritin 466.45 (174.40-886.90) vs. 279 microg/L (137.00-648.50), p: 0.06]. A significant decrease of TNF-alpha [2.30 pg/ml (1.48-2.95) vs. 1.65 pg/ml (0.11-1.96), p: 0.01] and IL6 levels [8.32 pg/ml (2.31-9.83) vs. 2.60 pg/ml (2.00-3.05), p: 0.01] was presented. After adjustment for confounding variables (age, sex, and Kt/v), a model consisting of BMI, ferittin, and TNF alpha accounted for 96% of the variance in HOMA-IR in Epo treated patients.The present study demonstrated that Epo treatment could participate in reducing insulin resistance through iron stores reduction and improvement of chronic inflammation in patients on maintenance HD." @default.
• W2213280957 created "2016-06-24" @default.
• W2213280957 creator A5001475783 @default.
• W2213280957 creator A5050938292 @default.
• W2213280957 creator A5059016624 @default.
• W2213280957 creator A5074370465 @default.
• W2213280957 creator A5085008346 @default.
• W2213280957 creator A5090442071 @default.
• W2213280957 date "2008-07-01" @default.
• W2213280957 modified "2023-09-26" @default.
• W2213280957 title "The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis." @default.
• W2213280957 cites W1551443142 @default.
• W2213280957 cites W1578612512 @default.
• W2213280957 cites W1924198296 @default.
• W2213280957 cites W1974925583 @default.
• W2213280957 cites W1975116315 @default.
• W2213280957 cites W1975299036 @default.
• W2213280957 cites W1977020764 @default.
• W2213280957 cites W1978811843 @default.
• W2213280957 cites W1990220461 @default.
• W2213280957 cites W2034100914 @default.
• W2213280957 cites W2052109773 @default.
• W2213280957 cites W2052698648 @default.
• W2213280957 cites W2069711307 @default.
• W2213280957 cites W2093880435 @default.
• W2213280957 cites W2097924350 @default.
• W2213280957 cites W2104098907 @default.
• W2213280957 cites W2106322486 @default.
• W2213280957 cites W2109223538 @default.
• W2213280957 cites W2112228232 @default.
• W2213280957 cites W2114416343 @default.
• W2213280957 cites W2132857214 @default.
• W2213280957 cites W2137891227 @default.
• W2213280957 cites W2146278956 @default.
• W2213280957 cites W2148625316 @default.
• W2213280957 cites W2160234571 @default.
• W2213280957 cites W2334794884 @default.
• W2213280957 cites W2336129563 @default.
• W2213280957 cites W2409617277 @default.
• W2213280957 cites W2444385342 @default.
• W2213280957 cites W2586813559 @default.
• W2213280957 cites W2607031541 @default.
• W2213280957 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2504398" @default.
• W2213280957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18923665" @default.
• W2213280957 hasPublicationYear "2008" @default.
• W2213280957 type Work @default.
• W2213280957 sameAs 2213280957 @default.
• W2213280957 citedByCount "11" @default.
• W2213280957 countsByYear W22132809572012 @default.
• W2213280957 countsByYear W22132809572014 @default.
• W2213280957 countsByYear W22132809572015 @default.
• W2213280957 countsByYear W22132809572017 @default.
• W2213280957 countsByYear W22132809572018 @default.
• W2213280957 crossrefType "journal-article" @default.
• W2213280957 hasAuthorship W2213280957A5001475783 @default.
• W2213280957 hasAuthorship W2213280957A5050938292 @default.
• W2213280957 hasAuthorship W2213280957A5059016624 @default.
• W2213280957 hasAuthorship W2213280957A5074370465 @default.
• W2213280957 hasAuthorship W2213280957A5085008346 @default.
• W2213280957 hasAuthorship W2213280957A5090442071 @default.
• W2213280957 hasConcept C126322002 @default.
• W2213280957 hasConcept C134018914 @default.
• W2213280957 hasConcept C153852466 @default.
• W2213280957 hasConcept C2776244011 @default.
• W2213280957 hasConcept C2777391703 @default.
• W2213280957 hasConcept C2777417653 @default.
• W2213280957 hasConcept C2778063415 @default.
• W2213280957 hasConcept C2778248108 @default.
• W2213280957 hasConcept C2778319317 @default.
• W2213280957 hasConcept C2778534260 @default.
• W2213280957 hasConcept C2778535154 @default.
• W2213280957 hasConcept C2778917026 @default.
• W2213280957 hasConcept C2779306644 @default.
• W2213280957 hasConcept C2779875672 @default.
• W2213280957 hasConcept C71924100 @default.
• W2213280957 hasConcept C90924648 @default.
• W2213280957 hasConceptScore W2213280957C126322002 @default.
• W2213280957 hasConceptScore W2213280957C134018914 @default.
• W2213280957 hasConceptScore W2213280957C153852466 @default.
• W2213280957 hasConceptScore W2213280957C2776244011 @default.
• W2213280957 hasConceptScore W2213280957C2777391703 @default.
• W2213280957 hasConceptScore W2213280957C2777417653 @default.
• W2213280957 hasConceptScore W2213280957C2778063415 @default.
• W2213280957 hasConceptScore W2213280957C2778248108 @default.
• W2213280957 hasConceptScore W2213280957C2778319317 @default.
• W2213280957 hasConceptScore W2213280957C2778534260 @default.
• W2213280957 hasConceptScore W2213280957C2778535154 @default.
• W2213280957 hasConceptScore W2213280957C2778917026 @default.
• W2213280957 hasConceptScore W2213280957C2779306644 @default.
• W2213280957 hasConceptScore W2213280957C2779875672 @default.
• W2213280957 hasConceptScore W2213280957C71924100 @default.
• W2213280957 hasConceptScore W2213280957C90924648 @default.
• W2213280957 hasIssue "3" @default.
• W2213280957 hasLocation W22132809571 @default.
• W2213280957 hasOpenAccess W2213280957 @default.
• W2213280957 hasPrimaryLocation W22132809571 @default.
• W2213280957 hasRelatedWork W2007952870 @default.
• W2213280957 hasRelatedWork W2013614352 @default.

• next